No, Trulicity is not a semaglutide. Trulicity contains the active ingredient dulaglutide, made by Eli Lilly. Semaglutide is a different molecule made by Novo Nordisk and sold under the brand names Ozempic (type 2 diabetes), Wegovy (chronic weight management), and Rybelsus (oral type 2 diabetes). Both drugs belong to the same drug class — GLP-1 receptor agonists — and act on the same target, but they have different chemical structures, half-lives, dose ranges, and side effect nuances. They are not interchangeable.
Quick Answer
Trulicity = dulaglutide. Semaglutide = a different molecule sold as Ozempic, Wegovy, and Rybelsus. Both are GLP-1 receptor agonists. Same drug class, different drugs.
Same Class, Different Molecules
Dulaglutide and semaglutide both belong to the GLP-1 receptor agonist class. They both bind the GLP-1 receptor and produce overlapping effects on glucose, weight, and the cardiovascular system. But they are not the same drug, just as ibuprofen and naproxen are both NSAIDs but are different molecules.
| Feature | Trulicity (dulaglutide) | Semaglutide |
|---|---|---|
| Generic name | Dulaglutide | Semaglutide |
| Brand names | Trulicity | Ozempic, Wegovy, Rybelsus |
| Manufacturer | Eli Lilly | Novo Nordisk |
| FDA approval | 2014 (T2D), 2020 (CV indication) | 2017 (Ozempic), 2021 (Wegovy) |
| Molecule type | GLP-1 peptide fused to IgG4 Fc fragment | Modified GLP-1 peptide with fatty acid chain |
| Route | Weekly subcutaneous injection (auto-injector pen) | Weekly SC injection (Ozempic, Wegovy) or daily oral (Rybelsus) |
| Half-life | ~5 days | ~7 days |
| Doses | 0.75, 1.5, 3.0, 4.5 mg weekly | 0.25, 0.5, 1.0, 2.0 mg (Ozempic); up to 2.4 mg (Wegovy); 3, 7, 14 mg (Rybelsus) |
| Indications | T2D + reduce MACE | T2D + reduce MACE (Ozempic); chronic weight management (Wegovy); T2D oral (Rybelsus) |
| Pediatric approval | Age 10+ (T2D) | Age 12+ (Wegovy) |
| Average A1C reduction | 1.0–1.6% | 1.0–2.0% |
| Average weight loss | 2–4 kg | 4–15 kg (depending on dose and indication) |
| Typical monthly cost (US) | $900–$1,100 | $950–$1,400 |
Where the Confusion Comes From
- Both treat type 2 diabetes and produce weight loss
- Both are once-weekly injections (excluding Rybelsus oral)
- Both share the same side effect profile (mainly GI)
- Both belong to the same drug class
- Media coverage often groups all GLP-1 drugs together — “Ozempic-like drugs,” “GLP-1 weight loss drugs”
- Pen device appearance is similar at a glance
- Both have similar contraindications (medullary thyroid carcinoma, MEN2)
How Their Structures Differ
Dulaglutide: Two modified GLP-1 peptides (each with amino acid changes resistant to DPP-4 breakdown) attached to a human IgG4 Fc fragment via a peptide linker. The Fc fragment dramatically extends circulation time by recycling through the FcRn neonatal Fc receptor pathway. Molecular weight is large — about 60 kDa.
Semaglutide: A modified GLP-1 peptide with two amino acid changes (Ala8Aib and Lys34Arg) and an attached C18 fatty diacid side chain on Lys26. The fatty acid allows tight binding to albumin in the blood, which slows clearance and prevents DPP-4 degradation. Molecular weight is much smaller — about 4 kDa. This smaller size and albumin binding strategy is what allows semaglutide to be formulated as an oral tablet (Rybelsus) when combined with the absorption enhancer SNAC.
Head-to-Head Effectiveness — SUSTAIN-7
The SUSTAIN-7 trial directly compared semaglutide and dulaglutide in adults with type 2 diabetes on metformin. Over 40 weeks:
| Outcome | Dulaglutide 0.75 mg | Semaglutide 0.5 mg | Dulaglutide 1.5 mg | Semaglutide 1.0 mg |
|---|---|---|---|---|
| A1C reduction | -1.1% | -1.5% | -1.4% | -1.8% |
| Weight loss | -2.3 kg | -4.6 kg | -3.0 kg | -6.5 kg |
| Reaching A1C below 7% | ~60% | ~70% | ~70% | ~80% |
| GI side effect rate | ~30% | ~40% | ~30% | ~45% |
Semaglutide produced slightly greater A1C reduction and weight loss at each comparison tier, but with somewhat higher rates of GI side effects. Both drugs were broadly well-tolerated. Note: this trial predated dulaglutide’s 3.0 mg and 4.5 mg doses, which may close some of the gap.
When Trulicity Might Be Preferred
- The auto-injector pen is one of the easiest to use — the needle is hidden, and patients do not have to attach a needle before each injection
- Pediatric approval down to age 10 for type 2 diabetes
- No dose adjustment needed for kidney function
- Slightly fewer GI side effects on average than semaglutide
- Insurance formulary may prefer Trulicity over Ozempic in some plans
When Semaglutide Might Be Preferred
- Larger A1C reduction needed
- Larger weight loss desired — particularly Wegovy or higher Ozempic doses
- Preference for an oral pill (Rybelsus) over an injection
- Larger and broader cardiovascular outcomes evidence (SUSTAIN-6, SELECT trials)
- Insurance formulary may prefer Ozempic over Trulicity in some plans
Switching Between Them
If switching from Trulicity to semaglutide (or vice versa), the change should be done under clinician guidance. There is no exact dose equivalence, but a common practical approach is:
- Stop Trulicity on its usual weekly dosing day
- Wait 7 days (one full Trulicity dose interval)
- Start semaglutide at its lowest dose (0.25 mg for Ozempic) and re-titrate every 4 weeks
- Monitor for breakthrough nausea or GI symptoms during the transition
- If transitioning the other way (semaglutide to Trulicity), start at 0.75 mg dulaglutide and titrate up as tolerated
This stepwise re-titration helps avoid both undertreatment and exaggerated GI side effects during the change.
Drugs in the Wider GLP-1 Class
Beyond Trulicity and semaglutide, the GLP-1 receptor agonist class includes:
- Liraglutide (Victoza, Saxenda) — daily injection
- Exenatide (Byetta twice daily, Bydureon BCise weekly)
- Lixisenatide (Adlyxin) — daily injection
- Tirzepatide (Mounjaro, Zepbound) — technically a dual GIP/GLP-1 agonist, not pure GLP-1, but often included in the broader GLP-1 conversation
Each of these is a distinct molecule with its own dosing schedule, indication set, and side effect profile. None is a semaglutide. For a class overview, see Trulicity class. For drug-vs-drug clarifications, see is metformin a semaglutide.
Cost and Coverage
Both Trulicity and the semaglutide brand family are expensive at retail (roughly 900 to 1,400 dollars per month). Insurance coverage varies widely. People should:
- Check insurance formulary — both Trulicity and Ozempic are often covered for type 2 diabetes
- Use manufacturer savings cards if eligible (Eli Lilly Trulicity Savings Card; Novo Nordisk Ozempic Savings Card)
- Be aware that Wegovy and Zepbound (weight loss indications) are less consistently covered than diabetes indications
- Discuss patient assistance programs with the prescriber if uninsured
Side Effect Profile Comparison
| Side Effect | Trulicity | Semaglutide (Ozempic) |
|---|---|---|
| Nausea | 12–21% | 15–25% |
| Vomiting | 6–12% | 5–10% |
| Diarrhea | 9–15% | 8–13% |
| Constipation | 4–8% | 5–10% |
| Abdominal pain | 6–10% | 7–12% |
| Decreased appetite | 4–9% | 6–12% |
| Injection site reactions | 0.5–2% | 0.5–2% |
| Pancreatitis | Rare, both classes carry the warning | Rare, both classes carry the warning |
| Gallbladder disease | Reported with both | Reported with both |
| Thyroid C-cell tumor warning | Yes (boxed) | Yes (boxed) |
Cardiovascular Outcomes
Both drugs have proven cardiovascular benefits in randomized outcomes trials:
- Dulaglutide (Trulicity) — REWIND trial showed a 12 percent reduction in major adverse cardiovascular events in T2D patients with or without established cardiovascular disease
- Semaglutide — SUSTAIN-6 trial showed a 26 percent reduction in MACE in T2D with cardiovascular risk factors; SELECT trial (2023) showed a 20 percent MACE reduction in adults with overweight/obesity and prior cardiovascular disease without diabetes
For broader context, see our A1C levels guide and treatment options.
What If You Were Told “Trulicity Is Like Ozempic”
The statement is half-right — they are in the same drug class and have many similar effects. But they are different molecules, made by different companies, with different doses and slightly different effectiveness and side effect profiles. They are not generic versions of each other. Switching from one to the other requires clinical attention to dose, titration, and tolerability.
The Bottom Line
No, Trulicity is not a semaglutide. Trulicity contains the active ingredient dulaglutide, made by Eli Lilly. Semaglutide is a different molecule made by Novo Nordisk and sold as Ozempic, Wegovy, and Rybelsus. Both belong to the GLP-1 receptor agonist drug class and act on the same target, but they have different chemical structures, dose ranges, and effectiveness. In head-to-head trials, semaglutide produced slightly greater A1C reduction and weight loss than dulaglutide at comparable tiers, while Trulicity has an easier-to-use auto-injector and a pediatric approval down to age 10. Both have proven cardiovascular benefits. They are not interchangeable, and switching between them should be done under clinician guidance with appropriate re-titration. Talk with your clinician about which GLP-1 receptor agonist fits your A1C, weight, kidney, and cost considerations.
